Oxford BioMedica
13
0
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
Role: lead
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
Role: collaborator
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Role: lead
TroVax Renal Immunotherapy Survival Trial
Role: lead
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Role: lead
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Role: lead
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
Role: collaborator
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
Role: lead
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
Role: collaborator
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Role: collaborator
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
Role: collaborator
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease
Role: lead
Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed
Role: collaborator
All 13 trials loaded